CYTH (Cyclo Therapeutics, Inc) Forvard P/S multiplikatori

Cyclo Therapeutics (CYTH) korporativ emblemasi va logotipi

Cyclo Therapeutics (CYTH) uchun xavflar potentsial sinovlarning muvaffaqiyatsizligi va gen terapiyasi bilan raqobatga bog'liq. Molekulalar uchun patentlar va FDA ning qat'iy nazorati himoya xususiyatlari vazifasini o'taydi. GURU.Markets saytidagi ushbu grafikda forward P/S ko'rsatkichi mavjud bo'lib, u yerda 23.60 ushbu metrikaning joriy qiymatini ko'rsatadi. Narxlarning bunday harakati klinik dasturlarning moslashuv davrida rahbariyatga bo'lgan barqaror ishonchni aks ettiradi.

Cyclo Therapeutics, Inc. - CYTH Forvard P/S multiplikatori (davr: 04.07.2022 - 05.04.2025)

Cyclo Therapeutics, Inc (CYTH) boʻyicha maʼlumotlarning jamlanma tahliliy kesimlari

- bozor narxi va tahlilchilarning maqsadli narxlari:
Kompaniyaning fundamental tahlili:Cyclo Therapeutics, Inc. CYTH
Cyclo Therapeutics, Inc original mahsuloti

Biotehnologiya sektori uchun Cyclo Therapeutics (CYTH) kompaniyasining kelgusidagi sotuvlarga nisbatan narx (price-to-sales) baholash dinamikasi kamyob dori vositalarini monetizatsiya qilish bo'yicha bozor kutuvlarining ko'rsatkichi bo'lib xizmat qiladi. Ushbu metrika joriy bozor kapitalizatsiyasining prognoz qilingan yillik daromadga nisbati sifatida hisoblanadi, bu esa choraklik hisobotlar orasidagi uzoq intervallarni chetlab o'tib, ilmiy kompetentsiyalar va klinik sinovlar bo'yicha ekspertlar shtatining qiymatini real vaqt rejimida baholash imkonini beradi.

Cyclo Therapeutics (CYTH) raqobatchilari

Narxning prognoz qilingan daromadga nisbati Vertex VRTX|ALNY (Alnylam Pharmaceuticals, Inc.) - Kelajakdagi narxning daromadga nisbati|Insmed Inc - Forvard P/S multiplikatori|Sotuvga nisbatan forvard narx UTHR (United Therapeutics Inc.)|BMRN: Forvard P/S multiplikatori|bridgebio.com (BBIO) - Forvard P/S multiplikatori|Narxning prognoz qilingan daromadga nisbati BGM Group Limited|COGT: Sotuvga nisbatan forvard narx|Narxning prognoz qilingan daromadga nisbati Xeris Biopharma Inc (XERS)|Forvard narx/daromad multiplikatori Keros Corp KROS|Forvard P/S multiplikatori ARCT (Arcturus Therapeutics)|Forvard P/S multiplikatori etonpharma.com ETON|Kamada - Forvard P/S multiplikatori|Fulcrum Therapeutics Inc (FULC) - Forvard narx/daromad multiplikatori|ABEO (abeonatherapeutics.com) - Forvard narx/daromad multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Mereo BioPharma Group plc (MREO)|PLX (Protalix BioTherapeutics) - Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori Pliant Rx (PLRX)|Narxning prognoz qilingan daromadga nisbati Applied Therapeutics, Inc. (APLT)|Narxning prognoz qilingan daromadga nisbati RNTX (Rein Therapeutics Inc.)|Narxning prognoz qilingan daromadga nisbati Gelteq GELS|Aytu BioPharma Inc (AYTU) - Bozor kapitallashuvining kelajakdagi daromadga nisbati|CMMB: Forvard narx/daromad multiplikatori|Sotuvga nisbatan forvard narx SRXH (SRx Health Solutions Inc.)|PLRZ (polyrizon-biotech.com) - Forvard narx/daromad multiplikatori|AEZS: Narxning kutilayotgan daromadga nisbati|INZY (Inozyme Pharma Inc.) - Forvard P/S multiplikatori|RPHM: Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori CSCI